市場調查報告書
商品編碼
1053722

全球心血管診斷測試市場增長機會/行業預測(2021-2030 年):按類型、面板、最終用戶

Cardiovascular Diagnostic Testing Market by Type, Panel, and End User : Global Opportunity Analysis and Industry Forecast, 2021-2030

出版日期: | 出版商: Allied Market Research | 英文 205 Pages | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

心血管診斷檢測市場規模將從2020年的68.7629億美元增長到2021-2030年8.3%的複合年增長率,預計到2030年將增長到154.3046億美元。

對各種心血管疾病的早期診斷和檢測需求增加、診斷工具的發展和進步、老年人口的增加、因久坐不動的生活方式而主訴心臟病發作和胸痛的患者數量增加等因素預計將在未來幾年推動市場。預計心血管疾病患病率的增加也將在預測期內提振市場。此外,心臟護理點 (POC) 測試的高精度、快速結果和經濟定價等優勢正在推動全球心血管診斷測試市場的增長。

本報告對全球心血管診斷檢測市場進行調查,並對市場進行定義和概述,分析市場影響因素、市場規模變化/預測、類型/最終用戶/地區/主要國家。總結了不同的細分市場、競爭環境、主要公司的簡介等。

目錄

第一章介紹

第2章執行摘要

第三章市場情況

  • 市場定義和範圍
  • 波特五力分析
  • 各大公司的定位
  • 市場動態
    • 促進因素
    • 抑製器
    • 市場機會
    • 影響分析
  • COVID-19 的影響

第 4 章心血管診斷檢測市場:按類型

  • 概覽
  • LDT(專有開發檢查)
    • 主要市場趨勢/增長因素/機會
    • 市場規模/預測:按地區
    • 市場份額分析:按國家/地區分類
    • 市場規模/預測:按類型
      • 脂蛋白檢測
      • 血管緊張素試驗
      • 纖維蛋白原檢測
      • 血清尿酸檢測
      • 高敏C反應蛋白(hs-CRP)
  • 體外診斷測試
    • 主要市場趨勢/增長因素/機會
    • 市場規模/預測:按地區
    • 市場分析:按國家/地區
    • 市場規模/預測:按類型
      • 心電圖(心電圖)
      • 超聲心動圖
      • 經食道超聲心動圖
      • 其他

第 5 章心血管診斷檢測市場:按面板

  • 概覽
  • 動脈粥樣硬化性心血管疾病 (ASCVD) 風險評估小組(Quest Diagnostics)
    • 主要市場趨勢/增長因素/機會
    • Cardio IQ 收入

第 6 章心血管診斷測試市場:按最終用戶

  • 概覽
  • 實驗室檢查設施
  • 學術機構
  • POC (Point of Care) 檢查設施
    • 市場規模/預測:按地區
    • 市場分析:按國家/地區

第 7 章心血管診斷檢測市場:按地區劃分

  • 概覽
  • 北美
  • 歐洲
  • 亞太地區
  • 拉丁美洲/中東/非洲
    • 主要市場趨勢/增長因素/機會
    • 市場規模/預測:按類型
    • 市場規模/預測:按最終用戶
    • 市場規模/預測:按國家/地區

第 8 章公司簡介

  • ABBOTT LABORATORIES
  • BECTON, DICKINSON AND COMPANY
  • BIOMERIEUX, INC.
  • BIO-RAD LABORATORIES, INC.
  • DANAHER CORPORATION
  • F. HOFFMANN-LA ROCHE LTD.
  • PERKINELMER INC.
  • SIEMENS AG
  • THERMO FISHER SCIENTIFIC, INC.
  • TOSOH CORPORATION
目錄
Product Code: A14287

The global cardiovascular diagnostic testing market was valued at $6,876.29 million in 2020, and is projected to reach $15,430.46 million by 2030, registering a CAGR of 8.3% from 2021 to 2030.

According to World Health Organization (WHO), cardiovascular diseases (CVDs) are a group of disorders of the heart and blood vessels and include coronary heart disease, cerebrovascular disease, rheumatic heart disease and other conditions. More than four out of five CVD deaths are due to heart attack and strokes and one third of these deaths occur prematurely in people under 70 years of age. Cardiovascular diagnostics refer to tests performed to examine, check, and monitor the heart condition if an individual is suffering from cardiovascular diseases or disorders. There is an extensive range of diagnostic tests available such as ECG, invasive & non-invasive tests, cardiovascular autonomic reflex test, and other laboratory tests.

Cardiovascular diseases are most commonly occurring health conditions these days and the prevention of cardiac diseases by monitoring the heart conditions via different diagnostic tools available such by using different serum-based tests and in-vitro diagnostic tools (electrocardiogram, echocardiograph, and transesophageal echocardiogram) is of immense importance for obtaining rapid results for immediate diagnosing and treatment. According to WHO, around 17.9 million people died from CVDs in 2016, representing 31% of all global deaths. Myocardial infarction is one of the conditions that occur due to cardiovascular diseases. It causes significant mortality and morbidity. A timely diagnosis of heart conditions allows clinicians to analyze the risk of their patients and prescribe relevant treatment.

Moreover, cardiovascular diseases claim more lives each year than all forms of cancer and chronic lower Respiratory Disease combined. For instance, according to American Heart Association (AHA), in 2017, Coronary Heart Disease was the leading cause (42.6%) of deaths attributable to cardiovascular disease in the US, followed by stroke (17.0%), high blood pressure (10.5%), heart failure (9.4%), diseases of the arteries (2.9%), and other cardiovascular diseases (17.6%). CVD is the leading global cause of death. CVD accounted for approximately 17.8 million deaths in 2017. This number is expected to grow to more than 22.2 million by 2030, according to a 2014 study. CVD and stroke accounted for 14% of total health expenditures in 2014 to 2015. This is more than any major diagnostic group.

There are several factors which influence the growth of the cardiovascular diagnostic testing market. Some of the key factors include rise in demand for the early diagnosis and testing of various cardiovascular diseases, development and advancement in diagnostic tools, growth in geriatric population and rising number of patients suffering from heart attacks & chest pain due to sedentary lifestyles are expected to drive the market in the coming years. Other key growth drivers include rise in the number of new cardiovascular cases diagnosed each year and increase in demand for disease-specific treatment in which cardiovascular diagnostic tools are used. Increasing prevalence of cardiovascular diseases is expected to boost the cardiovascular diagnostic testing market during the forecast period. According to World Health Organization, about 17.7 million people die each year from cardiovascular diseases (CVDs) and it is estimated to be the cause of 31% of the total deaths worldwide. Around 80% of all CVD deaths is due to heart attacks and strokes.

Furthermore, ability of cardiac markers for accurate and rapid prediction of heart failure after the onset of chest pain has added boost to the market growth. In addition, promising features such as high accuracy, quick outcomes and economic pricing of cardiac point of care (POC) testing is driving the growth of cardiovascular diagnostic testing market, globally.

However, the development of other methods for diagnosis of cardiovascular diseases, along with high cost of procedure, lack of full proof assurance, and steep competition among existing players are anticipated to restrain the cardiovascular diagnostic testing market growth during the forecast period.

The global cardiovascular diagnostic testing market is segmented into type, panel, end user, and region. On the basis of type, the market is categorized into Laboratory developed test and In-Vitro diagnostic test. Laboratory developed test is further categorized into lipoprotein test, angiotensin test, fibrinogen test, serum uric acid test, and high-sensitivity c-reactive protein (hsCRP). In-vitro diagnostic test is further categorized into electrocardiogram test, echocardiography test, transesophageal echocardiogram test, and others. Furthermore, the panel segment includes Atherosclerotic cardiovascular disease (ASCVD) risk panel with score and end user segment is divided into Laboratory testing facilities, Academic institutes and Point-of-care testing facilities. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Some of the major companies that operate in the global cardiovascular diagnostic testing market are Abbott Laboratories, Becton, Dickinson and Company, bioMerieux, Inc., Bio-Rad Laboratories Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd, PerkinElmer Inc., Siemens AG, Thermo Fisher Scientific Inc., and Tosoh Corporation.

KEY BENEFITS FOR STAKEHOLDERS

  • The study provides an in-depth analysis of the global cardiovascular diagnostic testing market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • A comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
  • Comprehensive quantitative analysis of the industry from 2020 to 2030 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
  • Extensive analysis of the key segments of the industry helps to understand the products and end users of cardiovascular diagnostic testing used across the globe.
  • Key market players and their strategies have been analysed to understand the competitive outlook of the market.

KEY MARKET SEGMENTS

By Type

  • Laboratory Developed Test
  • Lipoprotein Test
  • Angiotensin Test
  • Fibrinogen Test
  • Serum Uric Acid Test
  • High-sensitivity C-reactive protein (hsCRP)
  • In-Vitro Diagnostic Test
  • Electrocardiogram Test
  • Echocardiography Test
  • Transesophageal Echocardiogram Test
  • Others

By Panel

  • Atherosclerotic cardiovascular disease (ASCVD) risk panel with score

By End User

  • Laboratory Testing Facilities
  • Academic Institutes
  • Point-of-Care Testing Facilities

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • Spain
  • Italy
  • UK
  • Rest of Europe
  • Asia-Pacific
  • Australia
  • Japan
  • India
  • China
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

KEY MARKET PLAYERS

  • Abbott Laboratories
  • Becton, Dickinson and Company
  • bioMerieux, Inc.
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd
  • PerkinElmer, Inc.
  • Siemens AG
  • Thermo Fisher Scientific, Inc.
  • Tosoh Corporation

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key benefits for stakeholders
  • 1.3.Key market segments
    • 1.3.1.List of key players profile in the report
  • 1.4.Research methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

  • 3.1.Market definition and scope
  • 3.2.Porters five forces analysis
    • 3.2.1.Top investment pockets
  • 3.3.Top player positioning, 2020
  • 3.4.Market dynamics
    • 3.4.1.Drivers
      • 3.4.1.1.Worldwide rise in geriatric population coupled with increasing prevalence of cardiovascular diseases
      • 3.4.1.2.Initiatives to spread awareness among patients
      • 3.4.1.3.Increasing Medical Technology Innovations
    • 3.4.2.Restraints
      • 3.4.2.1.Limited insurance coverage and high cost of devices
      • 3.4.2.2.Changes in FDA regulation and guidance of LDTs
    • 3.4.3.Opportunity
      • 3.4.3.1.Improvement in healthcare infrastructure in emerging nations
    • 3.4.4.Impact analysis
  • 3.5.Analysis of COVID-19-Impact on the Market

CHAPTER 4:CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY TYPE

  • 4.1.Overview
    • 4.1.1.Market size and forecast
  • 4.2.Laboratory developed test
    • 4.2.1.Key market trends, growth factors, and opportunities
    • 4.2.2.Market size and forecast, by region
    • 4.2.3.Market share analysis, by country
    • 4.2.4.Market size and forecast, by type
      • 4.2.4.1.Lipoprotein Test
      • 4.2.4.1.1.Market size and forecast
      • 4.2.4.2.Angiotensin Test
      • 4.2.4.2.1.Market size and forecast
      • 4.2.4.3.Fibrinogen Test
      • 4.2.4.3.1.Market size and forecast
      • 4.2.4.4.Serum Uric Acid Test
      • 4.2.4.4.1.Market size and forecast
      • 4.2.4.5.High-sensitivity C-reactive protein (hs-CRP)
      • 4.2.4.5.1.Market size and forecast
  • 4.3.In-Vitro diagnostic test
    • 4.3.1.Key market trends, growth factors, and opportunities
    • 4.3.2.Market size and forecast, by region
    • 4.3.3.Market analysis, by country
    • 4.3.4.Market size and forecast, by type
      • 4.3.4.1.Electrocardiogram Test (ECG)
      • 4.3.4.1.1.Market size and forecast
      • 4.3.4.2.Echocardiography Test
      • 4.3.4.2.1.Market size and forecast
      • 4.3.4.3.Transesophageal Echocardiogram Test
      • 4.3.4.3.1.Market size and forecast
      • 4.3.4.4.Others
      • 4.3.4.4.1.Market size and forecast

CHAPTER 5:CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY PANEL

  • 5.1.Overview
  • 5.2.Atherosclerotic Cardiovascular Disease (ASCVD) Risk Panel with Score (Quest Diagnostics)
    • 5.2.1.Key market trends, growth factors, and opportunities
    • 5.2.2.Cardio IQ Revenue, 2020

CHAPTER 6:CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY END USER

  • 6.1.Overview
    • 6.1.1.Market size and forecast
  • 6.2.Laboratory testing facilities
    • 6.2.1.Market size and forecast, by region
    • 6.2.2.Market analysis, by country
  • 6.3.Academic Institutes
    • 6.3.1.Market size and forecast, by region
    • 6.3.2.Market analysis, by country
  • 6.4.Point-of-care testing facilities
    • 6.4.1.Market size and forecast, by region
    • 6.4.2.Market analysis, by country

CHAPTER 7:CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY REGION

  • 7.1.Overview
    • 7.1.1.Market size and forecast
  • 7.2.North America
    • 7.2.1.Key market trends, growth factors, and opportunities
    • 7.2.2.North America market size and forecast, by Type
    • 7.2.3.North America market size and forecast, by end user
    • 7.2.4.Market size and forecast, by country
      • 7.2.4.1.U.S.
      • 7.2.4.1.1.U.S. Cardiovascular diagnostic testing market, by type
      • 7.2.4.1.2.U.S. Cardiovascular diagnostic testing market, by end user
      • 7.2.4.2.Canada
      • 7.2.4.2.1.Canada Cardiovascular diagnostic testing market, by Type
      • 7.2.4.2.2.Canada Cardiovascular diagnostic testing market, by end user
      • 7.2.4.3.Mexico
      • 7.2.4.3.1.Mexico Cardiovascular diagnostic testing market, by Type
      • 7.2.4.3.2.Mexico Cardiovascular diagnostic testing market, by end user
  • 7.3.Europe
    • 7.3.1.Key market trends, growth factors, and opportunities
    • 7.3.2.Europe market size and forecast, by Type
    • 7.3.3.Europe market size and forecast, by end user
    • 7.3.4.Market size and forecast, by country
      • 7.3.4.1.Germany
      • 7.3.4.1.1.Germany Cardiovascular Diagnostic Testing market, by Type
      • 7.3.4.1.2.Germany Cardiovascular Diagnostic Testing market, by end user
      • 7.3.4.2.France
      • 7.3.4.2.1.France Cardiovascular Diagnostic Testing market, by Type
      • 7.3.4.2.2.France Cardiovascular Diagnostic Testing market, by end user
      • 7.3.4.3.UK
      • 7.3.4.3.1.UK Cardiovascular Diagnostic Testing market, by Type
      • 7.3.4.3.2.UK Cardiovascular Diagnostic Testing market, by end user
      • 7.3.4.4.Italy
      • 7.3.4.4.1.Italy Cardiovascular Diagnostic Testing market, by Type
      • 7.3.4.4.2.Italy Cardiovascular Diagnostic Testing market, by end user
      • 7.3.4.5.Spain
      • 7.3.4.5.1.Spain Cardiovascular Diagnostic Testing market, by Type
      • 7.3.4.5.2.Spain Cardiovascular Diagnostic Testing market, by end user
      • 7.3.4.6.Rest of Europe
      • 7.3.4.6.1.Rest of Europe Cardiovascular Diagnostic Testing market, by Type
      • 7.3.4.6.2.Rest of Europe Cardiovascular Diagnostic Testing market, by end user
  • 7.4.Asia-Pacific
    • 7.4.1.Key market trends, growth factors, and opportunities
    • 7.4.2.Asia-Pacific market size and forecast, by Type
    • 7.4.3.Asia-Pacific market size and forecast, by end user
    • 7.4.4.Market size and forecast, by country
      • 7.4.4.1.Japan
      • 7.4.4.1.1.Japan Cardiovascular Diagnostic Testing market, by Type
      • 7.4.4.1.2.Japan Cardiovascular Diagnostic Testing market, by end user
      • 7.4.4.2.China
      • 7.4.4.2.1.China Cardiovascular Diagnostic Testing market, by Type
      • 7.4.4.2.2.China Cardiovascular Diagnostic Testing market, by end user
      • 7.4.4.3.India
      • 7.4.4.3.1.India Cardiovascular Diagnostic Testing market, by Type
      • 7.4.4.3.2.India Cardiovascular Diagnostic Testing market, by end user
      • 7.4.4.4.Australia
      • 7.4.4.4.1.Australia Cardiovascular Diagnostic Testing market, by Type
      • 7.4.4.4.2.Australia Cardiovascular Diagnostic Testing market, by end user
      • 7.4.4.5.South Korea
      • 7.4.4.5.1.South Korea Cardiovascular Diagnostic Testing market, by Type
      • 7.4.4.5.2.South Korea Cardiovascular Diagnostic Testing market, by end user
      • 7.4.4.6.Rest of Asia-Pacific
      • 7.4.4.6.1.Rest of Asia-Pacific Cardiovascular Diagnostic Testing market, by Type
      • 7.4.4.6.2.Rest of Asia-Pacific Cardiovascular Diagnostic Testing market, by end user
  • 7.5.LAMEA
    • 7.5.1.Key market trends, growth factors, and opportunities
    • 7.5.2.LAMEA market size and forecast, by Type
    • 7.5.3.LAMEA market size and forecast, by end user
    • 7.5.4.Market size and forecast, by country
      • 7.5.4.1.Brazil
      • 7.5.4.1.1.Brazil Cardiovascular Diagnostic Testing market, by Type
      • 7.5.4.1.2.Brazil Cardiovascular Diagnostic Testing market, by end user
      • 7.5.4.2.Saudi Arabia
      • 7.5.4.2.1.Saudi Arabia Cardiovascular Diagnostic Testing market, by Type
      • 7.5.4.2.2.Saudi Arabia Cardiovascular Diagnostic Testing market, by end user
      • 7.5.4.3.South Africa
      • 7.5.4.3.1.South Africa Cardiovascular Diagnostic Testing market, by Type
      • 7.5.4.3.2.South Africa Cardiovascular Diagnostic Testing market, by end user
      • 7.5.4.4.Rest of LAMEA
      • 7.5.4.4.1.Rest of LAMEA Cardiovascular Diagnostic Testing market, by Type
      • 7.5.4.4.2.Rest of LAMEA Cardiovascular Diagnostic Testing market, by end user

CHAPTER 8:COMPANY PROFILES

  • 8.1.ABBOTT LABORATORIES
    • 8.1.1.Company overview
    • 8.1.2.Company snapshot
    • 8.1.3.Operating business segments
    • 8.1.4.Product portfolio
    • 8.1.5.Business performance
  • 8.2.BECTON, DICKINSON AND COMPANY
    • 8.2.1.Company overview
    • 8.2.2.Company snapshot
    • 8.2.3.Operating business segments
    • 8.2.4.Product portfolio
    • 8.2.5.Business performance
  • 8.3.BIOMERIEUX, INC.
    • 8.3.1.Company overview
    • 8.3.2.Company snapshot
    • 8.3.3.Operating business segments
    • 8.3.4.Product portfolio
    • 8.3.5.Business performance
  • 8.4.BIO-RAD LABORATORIES, INC.
    • 8.4.1.Company overview
    • 8.4.2.Company snapshot
    • 8.4.3.Operating business segments
    • 8.4.4.Product portfolio
    • 8.4.5.Business performance
  • 8.5.DANAHER CORPORATION
    • 8.5.1.Company overview
    • 8.5.2.Company snapshot
    • 8.5.3.Operating business segments
    • 8.5.4.Product portfolio
    • 8.5.5.Business performance
  • 8.6.F. HOFFMANN-LA ROCHE LTD.
    • 8.6.1.Company overview
    • 8.6.2.Company snapshot
    • 8.6.3.Operating business segments
    • 8.6.4.Product portfolio
    • 8.6.5.Business performance
  • 8.7.PERKINELMER INC.
    • 8.7.1.Company overview
    • 8.7.2.Company snapshot
    • 8.7.3.Operating business segments
    • 8.7.4.Product portfolio
    • 8.7.5.Business performance
  • 8.8.SIEMENS AG
    • 8.8.1.Company overview
    • 8.8.2.Company snapshot
    • 8.8.3.Operating business segments
    • 8.8.4.Product portfolio
    • 8.8.5.Business performance
  • 8.9.THERMO FISHER SCIENTIFIC, INC.
    • 8.9.1.Company overview
    • 8.9.2.Company snapshot
    • 8.9.3.Operating business segments
    • 8.9.4.Product portfolio
    • 8.9.5.Business performance
  • 8.10.TOSOH CORPORATION
    • 8.10.1.Company overview
    • 8.10.2.Company snapshot
    • 8.10.3.Operating business segments
    • 8.10.4.Product portfolio
    • 8.10.5.Business performance

LIST OF TABLES

  • TABLE 01.GLOBAL CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 02.CARDIOVASCULAR DIAGNOSTIC TESTING MARKET FOR LABORATORY DEVELOPED TEST, BY REGION, 2020-2030 ($MILLION)
  • TABLE 03.CARDIOVASCULAR DIAGNOSTIC TESTING MARKET REVENUE FOR LABORATORY DEVELOPED TEST, BY TYPE 2020-2030 ($MILLION)
  • TABLE 04.CARDIOVASCULAR DIAGNOSTIC TESTING MARKET FOR IN VITRO DIAGNOSTIC TEST, BY REGION, 2020-2030 ($MILLION)
  • TABLE 05.CARDIOVASCULAR DIAGNOSTIC TESTING MARKET REVENUE FOR IN VITRO DIAGNOSTIC TEST, BY TYPE 2020-2030 ($MILLION)
  • TABLE 06.CARDIO IQ REVENUE, 2020 (US$)
  • TABLE 07.CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 08.CARDIOVASCULAR DIAGNOSTIC TESTING MARKET FOR LABORARTORY TESTING FACILITIES, BY REGION, 2020-2030 ($MILLION)
  • TABLE 09.CARDIOVASCULAR DIAGNOSTIC TESTING MARKET FOR ACADEMIC INSTITUES, BY REGION, 2020-2030 ($MILLION)
  • TABLE 10.CARDIOVASCULAR DIAGNOSTIC TESTING MARKET FOR POINT OF CARE TESTING (POCT) FACILITIES, BY REGION, 2020-2030 ($MILLION)
  • TABLE 11.CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 12.NORTH AMERICA CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 13.NORTH AMERICA CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 14.NORTH AMERICA CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 15.U.S. CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 16.U.S. CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 17.CANADA CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 18.CANADA CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 19.MEXICO CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 20.MEXICO CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 21.EUROPE CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 22.EUROPE CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 23.EUROPE CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 24.GERMANY CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 25.GERMANY CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 26.FRANCE CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 27.FRANCE CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 28.UK CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 29.UK CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 30.ITALY CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 31.ITALY CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 32.SPAIN CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 33.SPAIN CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 34.REST OF EUROPE CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 35.REST OF EUROPE CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 36.ASIA-PACIFIC CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 37.ASIA-PACIFIC CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 38.ASIA-PACIFIC CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 39.JAPAN CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 40.JAPAN CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 41.CHINA CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 42.CHINA CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 43.INDIA CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 44.INDIA CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 45.AUSTRALIA CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 46.AUSTRALIA CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 47.SOUTH KOREA CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 48.SOUTH KOREA CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 49.REST OF ASIA-PACIFIC CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 50.REST OF ASIA-PACIFIC CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 51.LAMEA CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 52.LAMEA CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 53.LAMEA CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 54.BRAZIL CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 55.BRAZIL CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 56.SAUDI ARABIA CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 57.SAUDI ARABIA CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 58.SOUTH AFRICA CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 59.SOUTH AFRICA CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 60.BRAZIL CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 61.REST OF LAMEA CARDIOVASCULAR DIAGNOSTIC TESTING MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 62.ABBOTT: COMPANY SNAPSHOT
  • TABLE 63.ABBOTT: OPERATING SEGMENTS
  • TABLE 64.ABBOTT: PRODUCT PORTFOLIO
  • TABLE 65.BD: COMPANY SNAPSHOT
  • TABLE 66.BD: OPERATING SEGMENTS
  • TABLE 67.BD: PRODUCT PORTFOLIO
  • TABLE 68.BIOMERIEUX, INC.: COMPANY SNAPSHOT
  • TABLE 69.BIOMERIEUX, INC.: OPERATING SEGMENTS
  • TABLE 70.BIOMERIEUX: PRODUCT PORTFOLIO
  • TABLE 71.BIO-RAD: COMPANY SNAPSHOT
  • TABLE 72.BIO-RAD: OPERATING SEGMENTS
  • TABLE 73.BIO RAD: PRODUCT PORTFOLIO
  • TABLE 74.DANAHER: COMPANY SNAPSHOT
  • TABLE 75.DANAHER: OPERATING SEGMENTS
  • TABLE 76.DANAHER: PRODUCT PORTFOLIO
  • TABLE 77.ROCHE: COMPANY SNAPSHOT
  • TABLE 78.ROCHE: OPERATING SEGMENTS
  • TABLE 79.ROCHE: PRODUCT PORTFOLIO
  • TABLE 80.PERKINELMER: COMPANY SNAPSHOT
  • TABLE 81.PERKINELMER: OPERATING SEGMENTS
  • TABLE 82.PERKINELMER PRODUCT PORTFOLIO
  • TABLE 83.SIEMENS: COMPANY SNAPSHOT
  • TABLE 84.SIEMENS: PRODUCT SEGMENTS
  • TABLE 85.SIEMENS: PRODUCT PORTFOLIO
  • TABLE 86.THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT
  • TABLE 87.THERMO FISHER SCIENTIFIC: OPERATING SEGMENTS
  • TABLE 88.THERMO FISHER SCIENTIFIC: PRODUCT PORTFOLIO
  • TABLE 89.TOSOH: COMPANY SNAPSHOT
  • TABLE 90.TOSOH: OPERATING SEGMENTS
  • TABLE 91.TOSOH: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01.GLOBAL CARDIOVASCULAR DIAGNOSTIC TESTING MARKET SEGMENTATION
  • FIGURE 02.HIGH BARGAINING POWER OF BUYERS
  • FIGURE 03.MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 04.MODERATE THREAT OF SUBSTITUTION
  • FIGURE 05.MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 06.MODERATE COMPETITVE RIVARLY
  • FIGURE 07.TOP INVESTMENT POCKETS, 2020
  • FIGURE 08.TOP PLAYER POSITIONING, 2020
  • FIGURE 09.IMPACT ANALYSIS
  • FIGURE 10.COMPARATIVE ANALYSIS OF CARDIOVASCULAR DIAGNOSTIC TESTING MARKET FOR LABORATORY DEVELOPED TEST, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 11.LIPOPROTEIN TEST MARKET, 2020-2030 ($MILLION)
  • FIGURE 12.ANGIOTENSIN TEST MARKET, 2020-2030 ($MILLION)
  • FIGURE 13.FIBRINOGEN TEST MARKET, 2020-2030 ($MILLION)
  • FIGURE 14.SERUM URIC ACID TEST MARKET, 2020-2030 ($MILLION)
  • FIGURE 15.SERUM URIC ACID TEST MARKET, 2020-2030 ($MILLION)
  • FIGURE 16.COMPARATIVE ANALYSIS OF CARDIOVASCULAR DIAGNOSTIC TESTING MARKET FOR IN VITRO DIAGNOSTIC TEST, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 17.ELECTROCARDIOGRAM TEST MARKET, 2020-2030 ($MILLION)
  • FIGURE 18.ECHOCARDIOGRAPHY TEST MARKET, 2020-2030 ($MILLION)
  • FIGURE 19.TRANSESOPHAGEAL ECHOCARDIOGRAM TEST MARKET, 2020-2030 ($MILLION)
  • FIGURE 20.OTHER TEST MARKET, 2020-2030 ($MILLION)
  • FIGURE 21.COMPARATIVE ANALYSIS OF CARDIOVASCULAR DIAGNOSTIC TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 22.COMPARATIVE ANALYSIS OF CARDIOVASCULAR DIAGNOSTIC TESTING MARKET FOR ACADEMIC INSTITUES, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 23.COMPARATIVE ANALYSIS OF CARDIOVASCULAR DIAGNOSTIC TESTING MARKET FOR POINT OF CARE OF TESTING (POCT), BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 24.ABBOTT: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 25.ABBOTT: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 26.ABBOTT: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 27.BD: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 28.BD: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 29.BD: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 30.BIOMERIEUX, INC.: REVENUE, 2018-2020 ($MILLION)
  • FIGURE 31.BIOMERIEUX: REVENUE SHARE BYSEGMENT, 2020 (%)
  • FIGURE 32.BIOMERIEUX: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 33.BIO-RAD: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 34.BIO-RAD: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 35.BIO-RAD: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 36.DANAHER: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 37.DANAHER: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 38.DANAHER: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 39.ROCHE: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 40.ROCHE: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 41.ROCHE: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 42.PERKINELMER: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 43.PERKINELMER: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 44.PERKINELMER: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 45.SIEMENS: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 46.SIEMENS: REVENUE SHARE BY PRODUCT SEGMENT, 2020 (%)
  • FIGURE 47.SIEMENS: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 48.THERMO FISHER SCIENTIFIC: REVENUE, 2018-2020 ($MILLION)
  • FIGURE 49.THERMO FISHER SCIENTIFIC: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 50.THERMO FISHER SCIENTIFIC: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 51.TOSOH: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 52.TOSOH: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 53.TOSOH: REVENUE SHARE BY REGION, 2020 (%)